Johnson & Johnson Income (Loss) from Continuing Operations, Per Diluted Share
Johnson & Johnson (JNJ) reported Income (Loss) from Continuing Operations, Per Diluted Share of $11.03 per share for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-02-11
- Johnson & Johnson income (loss) from continuing operations, per diluted share for the quarter ending 2024-09-29 was $1.11, a 34.32% decline year-over-year.
- Johnson & Johnson income (loss) from continuing operations, per diluted share for the quarter ending 2024-06-30 was $1.93, a 5.85% decline year-over-year.
- Johnson & Johnson income (loss) from continuing operations, per diluted share for the quarter ending 2024-03-31 was $1.34.
- Johnson & Johnson income (loss) from continuing operations, per diluted share for the quarter ending 2023-12-31 was $1.70, a 39.34% increase year-over-year.
- Johnson & Johnson income (loss) from continuing operations, per diluted share for fiscal 2025 was $11.03, a 90.50% increase from fiscal 2024.
- Johnson & Johnson income (loss) from continuing operations, per diluted share for fiscal 2024 was $5.79, a 11.35% increase from fiscal 2023.
- Johnson & Johnson income (loss) from continuing operations, per diluted share for fiscal 2023 was $5.20, a 15.31% decline from fiscal 2023.
- Johnson & Johnson income (loss) from continuing operations, per diluted share for fiscal 2023 was $6.14, a 7.81% decline from fiscal 2022.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2025-12-28 | $11.03 10-K · filed 2026-02-11 | |||
| 2024-12-29 | $5.79 10-K · filed 2026-02-11 | |||
| 2024-09-29 | $1.11 10-Q · filed 2024-10-23 | $4.38 10-Q · filed 2024-10-23 | ||
| 2024-06-30 | $1.93 10-Q · filed 2024-07-25 | $3.27 10-Q · filed 2024-07-25 | ||
| 2024-03-31 | $1.34 10-Q · filed 2024-05-01 | |||
| 2023-12-31 | $1.70 10-K · filed 2024-02-16 | $5.20 10-K · filed 2026-02-11 | ||
| 2023-10-01 | $1.69 10-Q · filed 2024-10-23 | $3.53 10-Q · filed 2024-10-23 | ||
| 2023-07-02 | $2.05 10-Q · filed 2024-07-25 | $1.86 10-Q · filed 2024-07-25 | ||
| 2023-04-02 | -$0.19 10-Q · filed 2024-05-01 | |||
| 2023-01-01 | $1.22 10-K · filed 2024-02-16 | $6.14 10-K · filed 2025-02-13 | ||
| 2022-10-02 | $1.62 10-K · filed 2024-02-16 | $4.93 10-Q · filed 2023-10-27 | ||
| 2022-07-03 | $1.60 10-K · filed 2024-02-16 | |||
| 2022-04-03 | $1.71 10-K · filed 2024-02-16 | |||
| 2022-01-02 | $6.66 10-K · filed 2024-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |